J&J's chemotherapy-free treatment for lung cancer gets US approval
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St set to open higher after August inflation report, oil price slide
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for 8% weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- White House copper tariff plan stalls amid affordability concerns, sources say
- Micron's Taiwan workers to get rewards worth up to 68 months of pay
- Crude Inventory 0.4M Barrels Last Week - EIA
- Vertiv shares drop on acquisition skepticism, AI pullback
- S&P 500, Dow futures attempt recovery ahead of inflation report
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Johnson & Johnson (JNJ) to acquire V-Wave in deal worth up to $1.7bn
August 20, 2024 8:40 AM EDT(Updated - August 20, 2024 11:13 AM EDT)
Johnson & Johnson (NYSE: JNJ) announced Tuesday that it has struck an agreement to acquire V-Wave Ltd., a privately-held company specializing in treatments for heart failure.
The deal will see Johnson & Johnson make an upfront payment of $600 million, with the potential for an additional $1.1 billion in milestone payments.
V-Wave will join Johnson &... More
Johnson & Johnson gets green light for lung cancer combination treatment
August 20, 2024 7:49 AM EDTJohnson & Johnson (NYSE: JNJ) announced Tuesday that it has received U.S. Food and Drug Administration (FDA) approval for a combination treatment of RYBREVANT and LAZCLUZE for the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations.
According to the company, it... More
